Alyssa Hamik
Physician Assistant · Missouri Valley, IANPI 1396208054
Payments from drug & device makers
Across 92 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$382
- AbbVie$229
- Novo Nordisk$213
- Vertex$106
- Bayer$93
- AstraZeneca$67
- plus $554 from 17 others
What the payments were for
- Food & beverage$1,63499%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 22 | $382 |
| AbbVie | 11 | $229 |
| Novo Nordisk | 10 | $213 |
| Vertex | 5 | $106 |
| Bayer | 5 | $93 |
| AstraZeneca | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Merck | 4 | $60 |
| Amgen | 4 | $54 |
| Astellas Pharma US Inc | 3 | $48 |
| Pfizer | 3 | $46 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Organon | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
How this compares
$1,646 in reported general payments places this provider in the 85th percentile of 1,140 physician assistant providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $32,299 |
| FarxigaDapagliflozin Propanediol | 40 | $31,161 |
| RybelsusSemaglutide | 26 | $25,385 |
| MounjaroTirzepatide | 22 | $23,764 |
| XareltoRivaroxaban | 31 | $21,466 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,770 |
| MyrbetriqMirabegron | 18 | $7,785 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,449 |
| Atorvastatin Calcium | 155 | $1,089 |
| Omeprazole | 81 | $912 |
| Gabapentin | 56 | $872 |
| Levothyroxine Sodium | 113 | $798 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $794 |
| Metoprolol Succinate | 47 | $680 |
| Potassium Chloride | 62 | $664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $213 | $57,68556 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $67 | $44,93258 claims |
| Lilly USA, LLCMounjaro | $382 | $23,76422 claims |
| Johnson & JohnsonXarelto | $13 | $21,46631 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $7,78518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,140 physician assistant providers in Iowa.
Other physician assistant in Missouri Valley
- Jayson GesulgaUrbandale$878K
- Laurie ClairJohnston$293K
- Katherine LemAmes$224K
- Laura CunninghamWest Des Moines$128K
- Michon LeddyClive$73K
- Kyle HawkinsIowa City$42K
- Andrew MetzgerIowa City$37K
- Myrl HolidaIowa City$37K
- Kelly MerchieDavenport$15K
- Kathleen DuffyClive$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.